Catalog3 refs
Tesamorelin
Growth Hormone SecretagogueGrowth Hormone / IGF-1 AxistherapeuticGHRH Analog | Visceral Fat ReductionMetabolicGrowth HormoneResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
Synthetic growth hormone-releasing hormone (GHRH) analog consisting of 44 amino acids with a trans-3-hexenoic acid modification that enhances stability by protecting against DPP-IV degradation. The only GHRH analog with FDA approval (2010), marketed as Egrifta for reducing excess visceral abdominal fat in HIV-positive adults with lipodystrophy. Stimulates the pituitary gland to produce and release GH through natural pulsatile mechanisms, preserving negative feedback.
Primary Uses
Reducing deep abdominal fat in patients with lipodystrophy
Reducing visceral adipose tissue (VAT)
Reducing liver fat (hepatic steatosis)
Improving liver enzymes (ALT, AST)
Improving triglyceride profiles
Increasing muscle density (proposed)
Stimulating growth hormone synthesis and pulsatile release
Increasing IGF-1 levels
Reduction of visceral adipose tissue (VAT) in HIV-associated lipodystrophy
Reduction of hepatic fat fraction in NAFLD
Improvement of cognitive function (executive function and verbal memory) in older adults
Improvement of cardiovascular markers (triglycerides, cholesterol/HDL ratio)
Supporting natural growth hormone production
HIV-associated lipodystrophy research
Visceral-fat reduction
GH axis studies
NAFLD and body-composition research
Cognitive function in older adults with MCI
Liver fat reduction in HIV-infected patients with NAFLD
HIV-Associated Lipodystrophy
Selective Visceral Fat Targeting
Sustained Fat Loss
Triglyceride Reduction
Cholesterol Profile Improvement
NAFLD Treatment
Lean Mass Preservation
IGF-1 Elevation
Cognitive Enhancement
Visceral fat reduction
Muscle preservation
Growth hormone release
Reduction of visceral abdominal fat in HIV-associated lipodystrophy
Improvement of lipid profiles
Reduction of liver fat
Potential visceral fat reduction in non-HIV adults with abdominal obesity (investigational)
Protocol Reference
Dose
1 mg daily
Frequency
Once Daily, 90 Minutes After Last Meal, Before Bed
Half-life
26-38 minutes
Route
Subcutaneous
Evidence
Human Clinical Data Available / Phase 4, FDA Approved / FDA-approved; Phase 3 clinical trials / FDA Approved / FDA-approved for HIV-associated lipodystrophy (disputed)
Research References· 23
Research Models
HumanRat
Also in Growth Hormone Secretagogue